Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy topic
No spam. Unsubscribe anytime.
Members press PEBB over denials as actuaries flag GLP‑1s and other pharmacy drivers
Summary
Public commenters described denials of specialty drugs and routine care; Seagull actuaries told the board GLP‑1 drugs are a major pharmacy cost driver and that adherent GLP‑1 users reduce some medical utilization but raise overall plan costs because of high drug prices.
Several public commenters used the board’s public‑comment period to press PEBB for better coverage of specialty medications and clearer transparency around plan decisions while Seagull actuaries presented data showing rising pharmacy costs driven by GLP‑1 drugs.
Noah Lowdermilk, a classified staff member at the University of Nevada, Reno, told the board he has ulcerative colitis and that specialty drug denials and prior‑authorization burdens have caused stress and health setbacks. “I pay every month for ‘coverage’ when the reality is that I’m met with more denials than the coverage they’re supposed to provide,” he said.
UMR and Seagull actuaries told the board the plan’s pharmacy trend is rising faster than member cost sharing, which shifts more of the burden to the plan. Seagull’s Debbie Donaldson and Amy McClendon showed that two GLP‑1 medicines accounted for a large share of pharmacy spend in the year analyzed, with an average allowed cost near $1,000 per 30‑day fill and an estimated plan impact of about $25 PMPM. The consultants found that while patients adherent to GLP‑1 therapy often used fewer emergency and urgent care services, the price of the drugs offset those medical savings.
Express Scripts representatives recommended tightening prior‑authorization rules for GLP‑1s by requiring physician chart documentation and A1C evidence of diabetes rather than a checkbox attestation. They told the board stricter documentation has reduced GLP‑1 spend in other public plans; one example cited showed a 28% reduction shortly after requiring chart notes.
Board members requested more granular analysis (including retrospective fraud/waste audits of current GLP‑1 claims, PA approval rates, and the time pharmacists spend reviewing records) before accepting new PMPM charges for enhanced clinical review.
What happens next: Staff and vendors agreed to return to the board with a deeper methodology write‑up, targeted audits of suspect claims, and estimates of likely savings from stricter GLP‑1 documentation and PA requirements.
